Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (110,219,885)	$ (29,372,119)
Adjustments to reconcile net loss to net cash used in operating activities:
Acquired in-process research and development	72,523,293
Depreciation and amortization	6,788	9,860
Stockbased compensation	16,923,911	5,722,651
Amortization of right of use lease asset	182,042	195,825
Foreign currency (gain) loss	(315,130)	(247,233)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	3,166,506	2,648,090
Accounts payable	(565,203)	(1,955,231)
Accrued expenses and other liabilities	(2,510,258)	(4,303,808)
Lease liability	(182,688)	(205,427)
Net cash used in operating activities	(20,990,624)	(27,507,392)
Cash flows from financing activities:
Proceeds from the exercise of stock options		86,970
Proceeds from at-the-market sales of common stock, net	584,447
Net cash provided by financing activities	584,447	86,970
Decrease in cash and cash equivalents	(20,406,177)	(27,420,422)
Effect of exchange rate changes on cash	442,726	(168,860)
Cash and cash equivalents-beginning of year	53,076,052	89,017,686
Cash and cash equivalents-end of period	33,112,601	61,428,404
Non-cash investing and financing activities:
Operating lease liabilities arising from obtaining right-of-use assets	113,612	$ 124,043
Issuance of convertible preferred stock and common stock in connection with acquisition	$ 70,107,167